Objective To explore the effects of semaglutide on blood glucose fluctuation,serum adipokines and visceral fat parameters in obesity patients with type 2 diabetes mellitus(T2DM).Methods A total of 106 obesity patients with T2DM treated in the hospital were retrospectively analyzed between June 2022 and January 2024.According to propensity matching method,they were divided into a combination group(metformin+semaglutide)and a metformin group(metformin),53 cases in each group.All patients were treated for 2 months.The curative effect in the two groups was compared.Results After treatment,total response rate of combination group was higher than that of metformin group(94.3％vs 79.3％,P＜0.05).The mean amplitude of glycemic excur-sion(MAGE),visfatin and visceral adiposity index(VAI)in combination group were lower than those in metformin group,while adipsin was higher than that in metformin group[(3.37±0.51)mmol/L vs(3.83±0.56)mmol/L,(65.35±6.28)μg/L vs(71.58±6.88)μg/L,(80.06±7.71)μg/L vs(85.19±8.12)μg/L,(5 013.55±413.61)ng/ml vs(4761.36±408.79)ng/ml,P＜0.05].After treatment,there was no difference in adverse reactions between the two groups(P＞0.05).Conclusion Semaglutide can control blood glucose fluctuation,regulate serum adipokines and improve visceral fat parameters in obesity patients with T2DM,which has high safety and effectiveness.
NETL
NSTL
万方数据
